Searchable abstracts of presentations at key conferences in endocrinology

ea0090p473 | Reproductive and Developmental Endocrinology | ECE2023

Change in lipid profile and glucose levels after 12 months of testosterone therapy in transgender men

Montanez Fernandez Laura , Bayona Cebada Ane

Introduction: Approximately 0.5% of the world population experiences gender dysphoria, a discrepancy between one’s biological sex and gender identity. Transgender men (TM), individuals who were assigned female at birth but who identify as men, can benefit from therapy with testosterone (T) to address gender dysphoria. Although unfavourable changes in lipid profiles have been previously reported, most studies did not show an adverse impact of testosterone treatment on fast...

ea0090ep589 | Endocrine-related Cancer | ECE2023

Alpelisib-induced severe hyperglycemia: A case report. Are we discontinuing the drug too soon?

Garcia Fernandez Javier , Perera Izquierdo Marcos

Background: Alpelisib is an α-selective PI3K inhibitor indicated for the treatment of postmenopausal women and men with hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2–), PIK3CA-mutated locally advanced or metastatic breast cancer following disease progression or after endocrine therapy. Hyperglycemia is the most common adverse event (up to 60%) associated with its use. It occurs more frequently and lasts longer in patients with pred...

ea0091oc10 | Oral Communications | SFEEU2023

Recurrent painful ovarian cysts: what should an endocrinologist be aware of?

Agarwal Mayuri , Fernandez Cornelius , Eapen Dilip

Case history: A 33 year old lady with irregular menstrual cycles and infertility presented to gynaecologist with recurrent abdominal pain and bloating. Her pain was found secondary to bilateral ovarian cysts. She had repeated laparoscopic ovarian cystectomies since 2018. In December 2021, modest hyperprolactinemia (1065MIU/L, RR 102-496) with negative macroprolactin test was noted, and MRI pituitary revealed 18x17x13mm pituitary macroadenoma. Cabergoline was started and she wa...

ea0031p371 | Thyroid | SFEBES2013

Factors affecting choice of definitive therapy in patients with relapsed thyrotoxicosis

Moussa Hend , Macias-Fernandez Elena , Joseph Stonny

The use of anti-thyroid medication is favoured first line therapy in Graves’ disease (GD). However, relapse rates are high (up to 50%) and definitive therapies of either surgery or radioactive Iodine therapy (RAI) are often considered following an informed decision. The definitive choice taken depends on several factors considered during the patient-doctor interaction. The aim of this study was thus to determine the influence of such factors.A cross...

ea0016p337 | Endocrine tumours | ECE2008

High prevalence of pituitary adenomas: a cross-sectional study in the city of Banbury (Oxfordshire)

Fernandez Alberto , Karavitaki Niki , Wass John AH

Background: Pituitary adenomas (PA) are considered very rare conditions, with an estimated prevalence of 25 cases/100 000 inhabitants. However, community-based studies on the prevalence of PA are currently scant.Aim: To ascertain the prevalence of PA and the characteristics of the patients diagnosed with them in a large population of inhabitants.Methods: A survey on the GP surgeries of Banbury (Oxfordshire, UK) covering 89 334 inha...

ea0015p228 | Pituitary | SFEBES2008

Epidemiology of pituitary adenomas: a cross-sectional study in the city of Banbury (Oxfordshire)

Fernandez Alberto , Karavitaki Niki , Wass John AH

Background: Pituitary adenomas (PA) have traditionally been considered as very rare conditions, with an estimated prevalence of 25 cases/100 000 inhabitants. However, these data have been extracted either from cancer registries or from hospital databases and therefore, may not be accurate.Aim: To ascertain the prevalence of PA and the characteristics of the patients diagnosed with them in a large population of inhabitants.Methods: ...

ea0032p712 | Neuroendocrinology | ECE2013

Effects of GH therapy in carbohydrate metabolism in spanish adults with GH deficiency

Andrea Parra Ramirez Paola , Perez Fernandez Laura , Fernandez Martinez Alberto , Grande Aragon Cristina , Alvarez-Escola Cristina

GH deficiency (GHD) in adults is characterized by a tendency towards fat mass gain and may predispose to type 2 diabetes mellitus.GH replacement (GHR) is associated with impaired insulin sensitivity shortly after starting therapy, reflected by increased fasting glucose and insulin levels. Available evidence suggests that concerns regarding glucose intolerance in patients receiving long-term GHR have not been substantiated. However, several environmental and lifestyle-related f...

ea0020p435 | Diabetes and Cardiovascular | ECE2009

Welfare activity in day diabetes hospital in our area: our experience in 2007

Serrano Isabel , Morales Cristobal , Garcia-Quiros Juan M , Fernandez Guillermo , Tome Monica , Fernandez Ignacio , Sendon Angel

Objectives: The daily diabetes hospital (DDH) is a functional device that offers to diabetics a close and customized attention by specialized staff. The objective is to evaluate the welfare activity, the diagnose and educative program of the DDH in 2007.Methodology: The following parameters have been analyzed: attended users, origin, main reason for consultation, previous Hba1c and to the 3 months, number revisions, income avoided, derivation place, tele...

ea0016p85 | Bone and calcium | ECE2008

Clinical and hormonal variables to predict bone mineral density loss in anorexia nervosa patients

Gonzalez Amalia , Varsavsky Mariela , Fernandez Ines Luque , Leyva Socorro , Palma Moya Mercedes , Soto Marisa Fernandez

Objective: Anorexia nervosa (AN) is often associated with severe mineral bone loss and increased risk of fractures. The objective of this study was to assess the bone mineral density (BMD) in patients with AN and its relationship with different anthropometrics, clinical and hormonal parameters.Patients and methods: We evaluated 47 women with AN according to criteria of DSM-IV. The anthropometrics variables measured were: weight (kg) height (m), BMI (kg/m...

ea0032oc3.4 | Thyroid | ECE2013

DNA methylation signatures identify biologically distinct thyroid cancer subtypes

Fernandez-Morera Juan Luis , Rodriguez-Rodero Sandra , Alvarez Elias Delgado , Fernandez-Fernandez Agustin , Fernandez-Vega Ivan , Gonzalez-Marquez Rocio , Sanchez-Rivas Veronica , Suarez-Gutierrez Lorena , Rodriguez Caballero Maria Galiana , Blanco Jessica Ares , Fernandez-Fraga Mario , Menendez-Torre Edelmiro

Introduction: The global patterns of aberrant DNA methylation in thyroid cancer are not known. In this study, we have used DNA methylation arrays to determine, for the first time, the genome-wide promoter methylation status of different subtypes of thyroid tumors.Material and methods: We analyzed a cohort of 54 snap frozen thyroid samples (thirteen papillary tumors, six follicular, eleven anaplastic, twenty medullar and four normal tissue samples). Also ...